To assess safety and tolerability, clinical effects of riociguat. To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactorily treated and cannot participate in any other CTEPH trial.

Registry ID

EUCTR2012-002104-40

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Bayer HealthCare AG

Start date

2013-04-16

Completion date

2015-12-01

Last update

2026-08-16

Conditions

• Chronic Trombo Embolic Pulmonary Hypertention
• Chronic Thromboembolic Pulmonary Hypertension

Summary

•To assess safety and tolerability, clinical effects of riociguat.. •To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactorily treated and cannot participate in any other CTEPH trial.

Locations

• , , Belgium
• , , Sweden
• , , Germany
• , , Czechia
• , , Spain
• , , Portugal
• , , Denmark
• , , Netherlands
• , , Italy
• , , Austria
• , , UK

Related clinical trials

• Chronic Thromboembolic Disease Registry
• Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients
• 129Xe MRI Cardiopulmonary
• Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension
• Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension
• Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism

View on source registry